Castle Biosciences Inc. has disclosed a series of stock transactions involving its President and Chief Executive Officer, Derek Maetzold. This update is significant as it sheds light on the executive's ownership changes and highlights the company's ongoing strategic decisions.
Background
Castle Biosciences Inc., classified under SIC 8071, provides medical laboratory services. The company is traded on the Nasdaq under the ticker symbol CSTL. Recent filings indicate a range of transactions, with the latest being reported on November 18, 2026.
What the Filing Says
According to the filing, Maetzold executed multiple transactions on November 16, 2026. He sold a total of 6,942 shares of Castle Biosciences common stock at a price of $32.92 per share. Following these transactions, Maetzold no longer holds shares directly.
Impact
These transactions may affect stakeholders, including investors and employees, as they reflect the company's executive ownership dynamics. The medical laboratories sector, in which Castle operates, may also be influenced by these changes, as they could signal shifts in strategic direction or confidence in the company's future.
What's Next
The filing does not say what happens next.
Details of the Transactions
On November 16, 2026, Derek Maetzold sold a total of 6,942 shares of common stock. This total includes three separate transactions: 3,904 shares, 1,642 shares, and 1,396 shares, all executed at a weighted-average price of $32.92 per share. The filing indicates that these transactions were executed under a Rule 10b5-1 plan that was adopted on June 2, 2026, which allows executives to set up a predetermined schedule for selling shares to avoid any potential allegations of insider trading.
Ownership Following Transactions
Following these transactions, Maetzold no longer holds any shares directly. However, he retains indirect ownership through various trusts. Notably, he has shares held by the Maetzold Descendants 2020 Trust, the Derek Maetzold 2020 Irrevocable Trust, and several other trusts established for his children. The filing details that these trusts collectively hold substantial amounts of common stock, indicating that while Maetzold has divested his direct ownership, he still maintains significant interests in the company through these vehicles.
Trusts Holding Shares
The filing lists multiple trusts that hold shares on behalf of Maetzold's family members, including the Maetzold 2018 Remainder Trusts for his children, which each hold 11,256 shares. Additionally, the DJM Grantor Retained Annuity Trusts hold varying amounts of shares, with Trust No. 6 holding 11,963 shares, Trust No. 7 holding 27,862 shares, Trust No. 8 holding 40,935 shares, and Trust No. 9 holding 23,216 shares. This structure suggests a strategic approach to estate planning and wealth management within the Maetzold family.
Conclusion
The filing provides a comprehensive overview of the recent transactions by Derek Maetzold, illustrating a shift in his direct ownership of Castle Biosciences Inc. while highlighting the ongoing trust structures that maintain his family's stake in the company. However, the filing does not include any information regarding the reasons behind these transactions or any future plans from the executive or the company.
Read Next
Afsari Nasym acquires 68,235 shares of Onterris, Inc.
Onterris, Inc. Chief Strategy Officer Acquires Shares
StubHub Holdings' Mark Streams Sells 76,891 Shares
Francesca M. Edwardson Transfers 25,000 Shares to Trust
Fitzgerald sells 21,580 shares of StubHub Holdings stock
Zatlyn Michelle files recent executive transaction details




